Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Beta Drugs Limited (BETA)
Small CapPharma stocks · Small cap · NSE
Beta Drugs Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result20 Jul, 06:57 pm IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
65BullishSMA20 -10.2% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 43
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
BETAD candles · FIT view+28.7%Latest close ₹1719.60 on 2026-10-19
Bar
-3.4%
RSI
33
MACD hist
-21.20
52W pos
40%
2026-10-19O ₹1779.80H ₹1779.80L ₹1700.00C ₹1719.60Vol 18,555 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
BETANifty PharmaNifty 500
- BETA
- -29.5%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -23.9 pp
Chart stats
19 Oct 2026- From 52W high
- -38.8%
- 52W range position
- 40%
- ATR (14)
- 6.8%
- Volume vs 20D
- 0.47x
- Avg traded value
- ₹7.4 Cr
- 20D price channel
- ₹1,625 - ₹2,233.9
₹2,807.9
₹990.1 - ₹2,807.9
₹117.5
Latest completed session
20-session average
54.3% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, while price trend supports entry. This looks more like momentum/speculation than a clean fundamental investment setup.
Weak U-Score but strong trend: momentum may be ahead of fundamentals.
Suggested next step
Momentum only
Trend is strong but fundamentals do not support a clean investment thesis.
U-Score
Legacy · WATCHLIST44
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Excellent90
Revenue +26.0% · PAT +33.3% YoY
Technical
Bullish65
Price trend and sector-relative-strength timing.
Valuation
Legacy model+12.5%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence69
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Excellent · 90/100Rev +26% YoY · PAT +33% YoY · margin expansion · +34% QoQ · operating leverage
Filed 30 Jun 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹126 Cr | +26.0% | +34.0% |
| EBITDA | ₹27 Cr | +35.0% | +50.0% |
| Operating margin | 22.0% | +200 bps | +300 bps |
| PAT | ₹16 Cr | +33.3% | +77.8% |
| PAT margin | 12.7% | +70 bps | +313 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 48.70
- P/B
- 8.32
- EV/EBITDA
- 23.47
- Market Cap
- 2222.00Cr
Profitability
- ROE
- 18.80%
- ROCE
- 19.20%
- ROA
- 9.27%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 27.00%
- EPS 5Y
- 29.00%
- Revenue 3Y
- 19.00%
- EPS 3Y
- 11.00%
Balance Sheet
- Debt/Equity
- 0.60
- Interest Coverage
- 5.53×
- Altman Z
- 7.53
- Book Value
- 241.00
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 5/5
- OCF
- 37.00 Cr
- EPS TTM
- 43.69
Shareholding
- Promoter Hold
- 59.10%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 56%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 385+6.4% vs prev
Net Profit
₹ CrLatest: 41.0-2.4% vs prev
Return on Equity
%Latest: 16.7-21.5% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
NeutralTrend is undirectional — long-term uptrend intact. RSI 33.
- Price above SMA200 (long-term uptrend) but mid-term MAs not aligned.
- SMA20 falling (~11.4% over last month) — short-term momentum negative.
- RSI(14) at 33 — sideways, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 39% off 52W high · 74% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
62
RS percentile
Stage 1 Base / Transition
1M return
-16.3%
3M return
-29.5%
6M return
+29.9%
1Y return
-8.1%
RS 1D
-5
RS 20D
-16
Sector rank
#1
Industry rank
#11
Stage evidence
- Price is within 6.4% of the 30-week proxy.
- The 30-week proxy changed +6.8% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price above
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 97.79-2.56%
RS vs Nifty 50098
Valuation & peers
U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 44 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation4/30
Growth15/25
Quality10/20
Balance Sheet6/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
44
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
44/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 12.5%.
- Growth contributes 15/25 to the score.
Main drags
- Valuation is weaker at 4/30; verify the latest quarterly trend.
- Balance sheet is weaker at 6/15; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
48.7
PB
8.3
EV/EBITDA
23.5
ROE
18.8%
ROCE
19.2%
FCF Yield
—
Debt/Equity
0.6
MoS
+12.5%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
44
Previous: 44
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+12.5%
Previous: +12.5%
Score history
12 stored score snapshots. Latest stored move: +2 points.
20 Oct 2026
v4.3-runtime-valuation
42
42
42
42
42
44
44
44
42
42
42
44
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹486.73
-253.3% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹1,966.05
+12.5% MoS
PEG
2.23
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
WINDLAS
Small
Windlas Biotech Limited
Pharmaceuticals
match 167
48
31.6
12.2%
+36%
FAIR VALUE
AHCL
Small
Anlon Healthcare Limited
Pharmaceuticals
match 165
41
52.5
18.4%
-11%
WATCHLIST
ALEMBICLTD
Small
Alembic Limited
Pharmaceuticals
match 165
58
8.4
13.0%
-21%
FAIR VALUE
JAGSNPHARM
Small
Jagsonpal Pharmaceuticals Limited
Pharmaceuticals
match 164
58
32.2
17.3%
+29%
FAIR VALUE
KOPRAN
Small
Kopran Limited
Pharmaceuticals
match 162
22
51.9
4.9%
-1785%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Beta Drugs Limited operates in Formulations, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
69Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 59th percentile of the scored universe and 46th percentile within Pharma. No major sub-score weakness stands out.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
22 docs text-extracted · 11 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
59th percentile
overall median 67 · Pharma: 46th pctile, median 70 · Small: 63rd pctile, median 66
Evidence depth
Financial-only
22 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
68
acceptable · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
66
acceptable · capital discipline
Results
63
acceptable · quarterly consistency
Trust positives
- ▸Promoter holding is 59.1%.
- ▸Promoter pledge is zero.
- ▸5 years of positive FCF.
- ▸OPM spread across recent quarters is 4%.
Trust risks
- ▸Promoter holding fell 7.6%.
- ▸ROCE trend is -7.1%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Beta Drugs Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationNov 2025
Nov 2025 · PPT
Source: Nse
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
Investor presentationNov 2024
Nov 2024 · PPT
Source: Nse
Concall transcriptNov 2024
Nov 2024 · Transcript
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.